Amyloid Beta 42/40 Ratio

Amyloid beta (Aβ) peptides are produced throughout the body as byproducts of normal amyloid precursor protein (APP) processing. APP is cleaved by enzymes called secretases, generating peptide fragments of varying lengths. The two most clinically relevant are Aβ40 (40 amino acids long) and Aβ42 (42 amino acids long). Aβ42 is more hydrophobic and more prone to aggregation than Aβ40, which is why Aβ42 is the primary component of the amyloid plaques that accumulate in Alzheimer's disease brains. When Aβ42 becomes trapped in brain plaques, less of it reaches the bloodstream, causing a decrease in circulating Aβ42 relative to Aβ40.

Measuring the ratio of Aβ42 to Aβ40 rather than Aβ42 alone significantly improves diagnostic accuracy. Individual Aβ42 levels vary widely between people due to differences in overall APP production, but the ratio normalizes for this individual variation by using Aβ40 as an internal reference. A decreased Aβ42/40 ratio in blood has been shown to correlate with amyloid-PET positivity — the current gold standard for confirming brain amyloid deposition — with concordance rates typically ranging from 80% to 90% in published studies.

Blood-based Aβ42/40 testing requires highly sensitive analytical platforms, as the absolute concentrations of these peptides in plasma are extremely low (in the picogram-per-milliliter range) and the difference between amyloid-positive and amyloid-negative individuals is relatively small. Mass spectrometry-based assays and advanced immunoassay platforms have achieved the analytical precision needed to make blood Aβ42/40 ratios clinically meaningful, though pre-analytical sample handling remains important for result reliability.

Prevena Health is exploring whether continuous or frequent monitoring of the Aβ42/40 ratio may provide insight into the dynamics of amyloid accumulation over time. Current clinical use of this ratio relies on single-point measurements that classify patients as amyloid-positive or amyloid-negative. Longitudinal tracking may reveal the rate at which the ratio changes, potentially identifying individuals in the transition zone between normal amyloid metabolism and pathological accumulation before they cross established diagnostic thresholds.

This approach may also support monitoring the biological effects of anti-amyloid therapies, where changes in the Aβ42/40 ratio over time could serve as an accessible pharmacodynamic marker. Prevena aims to investigate whether wearable biosensor technology can achieve the analytical sensitivity needed for reliable amyloid beta peptide quantification in the ambulatory setting, complementing the existing ecosystem of laboratory-based blood tests for Alzheimer's biomarkers.